Arcellx, Inc. announced new clinical data from its Phase 1 and iMMagine-1 studies on anito-cel for multiple myeloma, to be presented at the American Society of Hematology Annual Meeting in December 2024, along with a webcast discussion.
AI Assistant
ARCELLX INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.